Guotai SSE STAR Brand Name Drug ETF

513120

512010

589720

510660

01255

159929

512200

Tata Health International has sold its entire share capital in Kong Tai Sundry Goods (BVI) to Wealthy Steps for HKD 1, effective immediately. This transaction removes the target group from Tata Health’s financial statements, which reported net liabilities of approximately HKD 4.1 million as of December 31, 2025. Tata Health anticipates an illustrative gain of about HKD 4.1 million from this sale.

PUBT

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

TATA HEALTH

China Universal 800 Health Care ETF

China Southern CSI All Share Real Estate ETF

Tata Health International sells Kong Tai Sundry Goods (BVI) to Wealthy Steps for HKD1

520500

159506

159992

159892

516500

562050

513700

516930

512290

159849

588130

Sunshine Lake Pharma Forecasts Turnaround to 2025 Profit

marketscreener

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI Biotechnology Theme ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

SUNSHINE PHARMA

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Sunshine Lake Pharma Forecasts Turnaround to 2025 Profit

00867

China Medical System Gets China Nod to Market Renal Anaemia Drug

China Medical System Gets China Nod to Market Renal Anaemia Drug

KBAB

Alibaba Health has granted 3,881,600 restricted share units (RSUs) to 20 employees under its 2024 Share Award Scheme. Each RSU allows the recipient to receive one share upon vesting, with no purchase price. The shares were valued at HKD 5.02 on the grant date and will vest over four years, with some vesting within 12 months. No performance targets are required for the RSUs.

KraneShares 2x Long BABA Daily ETF

Health Care Select Sector SPDR

BABA 2x Long Daily ETF - GraniteShares

iShares US Healthcare Providers

Alibaba HK SDR 5to1

Dacheng CSI All Share Health Care Equipment and Services ETF

SPDR S&P Health

VG Health

ALI HEALTH

BABA-W

Alibaba

Alibaba Health Grants 3.88 million RSUs Under 2024 Share Award Scheme

Pak Fah Yeow Forecasts Rise in 2025 Profit

PAK FAH YEOW

Pak Fah Yeow Forecasts Rise in 2025 Profit

Pak Fah Yeow International expects consolidated net profit attributable of HK$91.3 million for year

Pak Fah Yeow International expects consolidated net profit attributable of HK$91.3 million for year

China Medical System announced that the NMPA has approved Desidustat tablets for treating anaemia in non-dialysis adult chronic kidney disease patients. This oral HIF-PHI drug enhances endogenous erythropoietin and improves iron availability. CMS International Development and Management, a subsidiary of China Medical System, secured an exclusive license for Desidustat from Zydus Lifesciences, effective January 20, 2020. The original content was published via the Hong Kong Stock Exchange.

China Medical System says China approves Desidustat tablets for CKD anaemia

Guangdong HEC Pharma anticipates a net profit of approximately RMB0.27 billion for FY2025, a significant turnaround from a net loss of RMB0.21 billion the previous year. This improvement is primarily attributed to increased demand for oseltamivir phosphate in the second half of 2025 due to rising influenza cases.

GD HEC CO.,LTD

Guangdong HEC Pharma expects FY2025 net profit attributable to parent of RMB0.27 billion

China's drug regulator has approved the world's first brain-computer interface (BCI) medical device for commercial use, developed by Borui Kang Medical Technology. This invasive BCI system aims to restore hand movement in patients with quadriplegia due to cervical spinal cord injuries. The device uses minimally invasive extradural implantation and wireless technology. Eligible patients must be aged 18 to 60, with specific spinal cord injuries. Clinical trials showed significant improvements in hand-grasping ability, enhancing patients' quality of life. The BCI sector is prioritized in China's latest five-year plan, with practical public use expected in three to five years.

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

ALPS Medical Breakthrough

iShares US Pharma

VanEck Pharmaceutical ETF

Invesco Pharmaceuticals ETF

Invesco Biotechnology & Genome ETF

GF CSI All Share Health Care ETF

SPDR Pharmac

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

China approves market launch of brain-computer interface medical device in world first

PA GOODDOCTOR welcomes four senior executives from Baidu Health to join collectively, with He Mingke serving as CEO, and Han Shuai, Zhang Yandong, and Peng Yu respectively responsible for operations, supply chain, medical business, and strategy. This move marks a significant breakthrough for PA GOODDOCTOR in the field of internet healthcare and reflects the industry's transformation towards an ecological closed loop and the integration of "insurance + healthcare." The addition of the team will significantly reduce the cost of adaptation and inject stable management and business momentum into the platform

腾讯新闻 - 财经

PA GOODDOCTOR

BIDU-SW

Baidu

Rare! Four key members of Baidu Health collectively join PA GOODDOCTOR

688256

688235

06160

588250

688428

588860

09969

The first batch of "graduates" from the Growth Tier of the STAR Market has arrived, with six companies achieving profitability and planning to delist from the U tier. These companies include Cambricon, BEONE MEDICINES, and INNOCARE, covering fields such as artificial intelligence and biomedicine. Cambricon's operating revenue in 2025 is expected to be 6.497 billion yuan, with a net profit of 2.059 billion yuan, while BEONE MEDICINES is projected to have an operating revenue of 38.205 billion yuan and a net profit of 1.422 billion yuan. The overall status of the 39 companies in the STAR Growth Tier shows a trend of "increased revenue and reduced losses," and it is expected that after the disclosure of the 2025 annual reports, the number of companies delisting from the "U" tier will reach 28

Cambricon

BeOne Medicines

BEONE MEDICINES

Penghua SSE STAR Biology and Medicine ETF

InnoCare Pharma

ICBCCS SSE STAR Biology and Medicine ETF

INNOCARE

The first batch of "graduates" from the Growth Sector of the STAR Market has arrived, with six companies achieving profitability and planning to delist from the U layer

562600

159883

159898

JD Health is investing heavily in AI tools to enhance its online pharmacy business, which accounted for 83% of its revenue. Despite strong earnings growth and a rise in active users, the company faces fierce competition from rivals like Alibaba Health and Meituan, which dominate the on-demand drug delivery market. JD Health has launched various AI-driven services, including AI doctors and pharmacists, to improve user experience and maintain market share. The company is also expanding its offline presence with over 300 self-operated pharmacies to integrate online and offline services.

- JD Health International Inc. has reported significant revenue growth, with online pharmacy sales constituting 83% of its turnover in 2025.  
- The company is integrating AI tools and expanding its pharmacy network, but faces fierce competition from rivals like Meituan and Alibaba Health, particularly in on-demand deliveries and AI-enhanced services.  
- Despite strong earnings, challenges remain as the healthcare tech landscape evolves, compelling JD Health to innovate and strengthen its market position.

benzinga_article

ChinaAMC CSI All Share Health Care Devices ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

JD HEALTH

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Meituan

MEITUAN

Will JD Health's AI Push Pay Off Amid Powerful Rivalry

159859

Sino Biopharmaceutical Unit's Biliary Tract Cancer Drug Trial Reaches Primary Endpoints of Survival

Tianhong CNI BIOMEDICINE ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

SINO BIOPHARM

Sino Biopharmaceutical Unit's Biliary Tract Cancer Drug Trial Reaches Primary Endpoints of Survival

Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor

SIHUAN PHARM PREF OFFER

Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor

Guotai SSE STAR Brand Name Drug ETF(589720.SH)

Tata Health International sells Kong Tai Sundry Goods (BVI) to Wealthy Steps for HKD1

Sunshine Lake Pharma Forecasts Turnaround to 2025 Profit

China Medical System Gets China Nod to Market Renal Anaemia Drug

Alibaba Health Grants 3.88 million RSUs Under 2024 Share Award Scheme

Pak Fah Yeow Forecasts Rise in 2025 Profit